Trending...
- AdvisorVault Releases New Explainer Video on their 17a-4 Managed 365 Service
- Introducing the Secret to Sustainable Weight Loss
- HuskyTail Digital Marketing Rings in Fall with Free SEO Audits for Local Businesses
IGH Naturals has initiated a clinical trial to evaluate Humolyte®, an oral solution aimed at reducing chemotherapy-related side effects and improving supportive care in oncology.
SACRAMENTO, Calif. - Californer -- Sacramento, CA — IGH Naturals, a leader in innovative hydration and recovery solutions, has begun enrollment of patients in a clinical trial evaluating the efficacy of its flagship product, Humolyte®, in alleviating common and debilitating side effects experienced by chemotherapy patients. The study is being conducted by a clinical research organization in India with multiple clinical sites and hospitals participating.
The study, which has received all necessary regulatory approvals, will enroll approximately 38 patients undergoing chemotherapy treatment. Most of these patients are at a high risk for developing mucositis (oral ulcers) from the chemotherapy. The study's primary focus is to assess Humolyte's ability to reduce symptoms of gastrointestinal distress including diarrhea, vomiting, as well as minimization of the severity of oral mucositis (mouth sores)—symptoms that frequently compromise patient comfort, hydration, and quality of life.
More on The Californer
In addition to symptom relief, the trial will also evaluate Humolyte's potential to reduce the need for frequent intravenous (IV) hydration in chemotherapy patients, a breakthrough that could significantly enhance patient convenience and reduce healthcare costs.
"We are committed to advancing supportive care in oncology and currently, there are no effective solutions in the market that can reduce the symptoms of mucositis while enhancing hydration of these patients at home," said Dr. Sourabh Kharait, the Founder and CEO of IGH Naturals. "This study represents an important step in validating Humolyte as a safe, effective, and patient-friendly solution for managing chemotherapy-related complications."
The trial is expected to generate critical data on both the efficacy and tolerability of Humolyte, helping to inform future treatment protocols and improve overall patient outcomes. The study is expected to complete enrollment by spring of 2026.
For more information about the study or HuMOLYTE's commitment to innovative patient care solutions, please visit [www.humolyte.com] or contact:
The study, which has received all necessary regulatory approvals, will enroll approximately 38 patients undergoing chemotherapy treatment. Most of these patients are at a high risk for developing mucositis (oral ulcers) from the chemotherapy. The study's primary focus is to assess Humolyte's ability to reduce symptoms of gastrointestinal distress including diarrhea, vomiting, as well as minimization of the severity of oral mucositis (mouth sores)—symptoms that frequently compromise patient comfort, hydration, and quality of life.
More on The Californer
- Steel Oak Coffee Launches First Interactive Coffee Flavor Wheel for Consumers
- NYC Public School Music Teacher & Singer-Songwriter Craig Klonowski Submits Five Songs for GRAMMY® Consideration
- City Council Candidates Unite Behind "Common Sense Contract with NYC"
- California High School Football Rankings Shaken Up After a Weekend of Upsets
- Courage Meets Conservation in the Last Horns of Africa on Documentary Showcase
In addition to symptom relief, the trial will also evaluate Humolyte's potential to reduce the need for frequent intravenous (IV) hydration in chemotherapy patients, a breakthrough that could significantly enhance patient convenience and reduce healthcare costs.
"We are committed to advancing supportive care in oncology and currently, there are no effective solutions in the market that can reduce the symptoms of mucositis while enhancing hydration of these patients at home," said Dr. Sourabh Kharait, the Founder and CEO of IGH Naturals. "This study represents an important step in validating Humolyte as a safe, effective, and patient-friendly solution for managing chemotherapy-related complications."
The trial is expected to generate critical data on both the efficacy and tolerability of Humolyte, helping to inform future treatment protocols and improve overall patient outcomes. The study is expected to complete enrollment by spring of 2026.
For more information about the study or HuMOLYTE's commitment to innovative patient care solutions, please visit [www.humolyte.com] or contact:
Source: IGH Naturals
Filed Under: Health
0 Comments
Latest on The Californer
- Fritz Coleman's Show "Unassisted Residency" celebrates two years at the El Portal Theatre
- California: No more loud commercials: Governor Newsom signs SB 576
- California celebrates National Coaches Day by revolutionizing youth sports with 25×25 Coaches Challenge
- Root Canal Specialist In Frederick Maryland Joins Pearlfection Dentistry
- Visions Museum of Textile Art presents Star Wars Galaxy's Edge Costume Lecture at Mesa College
- Eastman Craighead Periodontics Expands Patient Access and Convenience with In-Network Insurance Partnerships and Complimentary Second Opinions
- ASIS San Francisco Named Chapter of the Year at 2025 Global Security Exchange
- RagMetrics Featured in IDC MarketScape for Generative AI Evaluation and Monitoring Technology
- LadyCakes Bakery Announces Release of New Children's Book with Local Celebration Events
- Heritage at South Brunswick Announces New Single-Family Home Collection
- Governor Newsom celebrates Manufacturing Month, highlighting California's dominant role in American manufacturing
- Mark Roher Law's Pre–Veterans Day Workshop for AI Bankruptcy Solutions Engages Over 1,000 Participants
- **Kenny Session Returns to Los Angeles for Inspiring Speaking Tour and Book Launch**
- Next Smile+Implant Launches New Website Enhancing Patient Care
- Media Companies and Book Publishing Companies could MAKE MILLIONS with this HALLOWEEN PROMOTION
- Cabrillo Economic Development Corporation Receives Three Awards at SCANPH Homes Within Reach Awards
- Why 5,000 People Are Rethinking Success After This TEDx Talk
- MDRN MUSE Cosmetic Dentistry Unveils New Website
- Birthday Launch the Hutchinson Fund's Earl Sr. and Nina Hutchinson Student Award
- Ford Family Foundation Awards One Circle Foundation Grant to Expand Youth Circles in Rural Oregon and Siskiyou County